CS
NXTC icon

Credit Suisse’s NextCure NXTC Stock Holding History

Credit Suisse’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,159
Closed -$151K – 4476
2020
Q4 		$151K Buy
1,159
+66
+6% +$8.53K ﹤0.01% 4141
2020
Q3 		$115K Buy
+1,093
New +$134K ﹤0.01% 3912
2020
Q2 		– Sell
-577
Closed -$256K – 4089
2020
Q1 		$256K Sell
577
-264
-31% -$141K ﹤0.01% 3517
2019
Q4 		$568K Buy
+841
New +$422K ﹤0.01% 3490

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Credit Suisse's NXTC Position: Q1 2021 in Review

Credit Suisse sold out of NextCure (NXTC) in Q1 2021, closing a stake of 1,159 shares — an estimated $151K sold.

Credit Suisse first reported a position in NXTC in Q4 2019 and held it in 4 quarters. The position peaked at $568K in Q4 2019. 92 funds tracked by Wall St. Rank hold NXTC as of Q1 2021.

  • Credit Suisse reported no remaining NextCure position as of Q1 2021 after selling out during the quarter.
  • Credit Suisse sold 1,159 NextCure shares in Q1 2021, an estimated $151K.
  • Credit Suisse first reported a position in NextCure in Q4 2019 and held it in 4 quarters.
  • Credit Suisse's NextCure position peaked at $568K in Q4 2019.
  • 92 funds tracked by Wall St. Rank held NextCure as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.